Across TCGA pan-cancer cohorts, MARCHF5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MARCHF5 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MARCHF5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MARCHF5 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where MARCHF5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	0.806	0.495	<.001	50	view →
CCRCC	DFS	Median	II,III,IV	0.534	0.836	.002	24	view →
LUAD	DFS	Quartile	II,III,IV	0.158	0.729	.010	7	view →
GBM	DFS	Quartile	All	0.612	0.357	.029	6	view →
LSCC	DFS	Median	II,III,IV	0.485	1.000	.006	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: MARCHF5 tumor-vs-normal RNA expression · all MARCHF5 data types